GlaxoSmithKline publishes positive phase III trial data for Nucala

GlaxoSmithKline has published positive phase III trial data for Nucala (mepolizumab), a drug it has developed for patients with the most severe forms of asthma.

The results of the pharmaceutical giant's phase IIIb MUSCA study were presented at the annual meeting of the American Academy of Allergy, Asthma and Immunology. They showed that Nucala was effective in improving the lung function and subsequently the quality of life of severe asthmatics when compared to a placebo.

After taking Nucala, patients were able to blow more air out of their lungs, indicating significantly improved lung function, and tended to be showing signs of fewer asthma-related symptoms.

Dr Frank Albers, medical affairs lead for the drug at GlaxoSmithKline, commented: "By demonstrating improvements in a range of important markers of asthma control … these data reinforce the valuable role Nucala can play in the treatment of some of the most severe asthma patients."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

Image: Remains' via iStock